| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Catheterization | 65 | 2025 | 518 | 12.960 |
Why?
|
| Pulmonary Valve | 20 | 2024 | 93 | 8.950 |
Why?
|
| Stents | 33 | 2025 | 502 | 8.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 16 | 2024 | 177 | 6.370 |
Why?
|
| Heart Valve Prosthesis | 14 | 2024 | 112 | 6.310 |
Why?
|
| Heart Defects, Congenital | 36 | 2024 | 757 | 5.540 |
Why?
|
| Septal Occluder Device | 16 | 2024 | 30 | 5.460 |
Why?
|
| Prosthesis Design | 29 | 2024 | 306 | 4.550 |
Why?
|
| Pulmonary Valve Insufficiency | 10 | 2024 | 40 | 4.550 |
Why?
|
| Pulmonary Artery | 20 | 2025 | 1095 | 4.200 |
Why?
|
| Heart Septal Defects, Atrial | 11 | 2024 | 52 | 4.070 |
Why?
|
| Aortic Coarctation | 10 | 2022 | 82 | 3.880 |
Why?
|
| Cardiac Surgical Procedures | 19 | 2021 | 499 | 3.020 |
Why?
|
| Pulmonary Veins | 8 | 2024 | 98 | 2.910 |
Why?
|
| Treatment Outcome | 86 | 2025 | 10202 | 2.840 |
Why?
|
| Hypoplastic Left Heart Syndrome | 7 | 2025 | 117 | 2.810 |
Why?
|
| Ventricular Outflow Obstruction | 5 | 2023 | 40 | 2.200 |
Why?
|
| Heart Atria | 5 | 2024 | 128 | 2.010 |
Why?
|
| Tetralogy of Fallot | 7 | 2022 | 78 | 1.900 |
Why?
|
| Vascular Fistula | 2 | 2024 | 22 | 1.790 |
Why?
|
| Hemodynamics | 25 | 2025 | 1090 | 1.770 |
Why?
|
| Heart Septal Defects, Ventricular | 5 | 2023 | 40 | 1.710 |
Why?
|
| Angioplasty, Balloon | 6 | 2020 | 91 | 1.710 |
Why?
|
| Angiography | 11 | 2021 | 196 | 1.570 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2024 | 76 | 1.570 |
Why?
|
| Retrospective Studies | 65 | 2025 | 14461 | 1.550 |
Why?
|
| Pulmonary Valve Stenosis | 4 | 2020 | 18 | 1.540 |
Why?
|
| Infant | 55 | 2025 | 8975 | 1.540 |
Why?
|
| Ductus Arteriosus | 4 | 2017 | 72 | 1.540 |
Why?
|
| Virtual Reality | 2 | 2024 | 52 | 1.510 |
Why?
|
| Cardiology | 5 | 2022 | 261 | 1.460 |
Why?
|
| Humans | 161 | 2025 | 129266 | 1.420 |
Why?
|
| Ductus Arteriosus, Patent | 8 | 2017 | 49 | 1.380 |
Why?
|
| Child | 70 | 2024 | 20785 | 1.290 |
Why?
|
| Heart Ventricles | 12 | 2024 | 781 | 1.280 |
Why?
|
| Echocardiography | 10 | 2023 | 629 | 1.210 |
Why?
|
| Child, Preschool | 43 | 2024 | 10459 | 1.210 |
Why?
|
| Predictive Value of Tests | 11 | 2025 | 1949 | 1.180 |
Why?
|
| Adolescent | 63 | 2024 | 20313 | 1.170 |
Why?
|
| Stenosis, Pulmonary Vein | 3 | 2023 | 17 | 1.160 |
Why?
|
| Heart Valve Diseases | 3 | 2019 | 152 | 1.140 |
Why?
|
| Male | 96 | 2025 | 63512 | 1.130 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2018 | 59 | 1.110 |
Why?
|
| Multimodal Imaging | 4 | 2024 | 110 | 1.110 |
Why?
|
| Pulmonary Atresia | 3 | 2023 | 20 | 1.080 |
Why?
|
| Computed Tomography Angiography | 2 | 2025 | 114 | 1.060 |
Why?
|
| Radiation Exposure | 3 | 2024 | 45 | 1.050 |
Why?
|
| Hypertension, Pulmonary | 9 | 2023 | 1894 | 1.010 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2025 | 41 | 1.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2017 | 197 | 1.010 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2024 | 282 | 0.990 |
Why?
|
| Catheterization, Peripheral | 2 | 2023 | 104 | 0.970 |
Why?
|
| Norwood Procedures | 2 | 2025 | 29 | 0.960 |
Why?
|
| Echocardiography, Doppler | 3 | 2025 | 108 | 0.950 |
Why?
|
| Multidetector Computed Tomography | 1 | 2025 | 33 | 0.930 |
Why?
|
| Endovascular Procedures | 5 | 2020 | 301 | 0.920 |
Why?
|
| Fistula | 1 | 2024 | 35 | 0.910 |
Why?
|
| Female | 86 | 2025 | 68551 | 0.910 |
Why?
|
| Embolization, Therapeutic | 2 | 2024 | 206 | 0.880 |
Why?
|
| Arteriovenous Malformations | 1 | 2024 | 27 | 0.870 |
Why?
|
| Fluoroscopy | 8 | 2024 | 156 | 0.870 |
Why?
|
| Prosthesis Failure | 4 | 2018 | 114 | 0.860 |
Why?
|
| Infant, Newborn | 24 | 2025 | 5736 | 0.850 |
Why?
|
| Mitral Valve Stenosis | 2 | 2016 | 18 | 0.850 |
Why?
|
| Amyloid | 2 | 2021 | 85 | 0.840 |
Why?
|
| Pericardial Effusion | 1 | 2023 | 21 | 0.830 |
Why?
|
| Echocardiography, Transesophageal | 8 | 2019 | 91 | 0.800 |
Why?
|
| Coronary Vessels | 4 | 2023 | 239 | 0.790 |
Why?
|
| Aorta, Thoracic | 3 | 2023 | 262 | 0.790 |
Why?
|
| Young Adult | 33 | 2024 | 12391 | 0.780 |
Why?
|
| Blood Pressure | 6 | 2021 | 1736 | 0.770 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2013 | 32 | 0.750 |
Why?
|
| Amyloidosis | 1 | 2021 | 42 | 0.740 |
Why?
|
| Intrinsically Disordered Proteins | 1 | 2021 | 29 | 0.740 |
Why?
|
| Radiography, Interventional | 7 | 2019 | 105 | 0.730 |
Why?
|
| Arteriovenous Fistula | 2 | 2024 | 35 | 0.720 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2022 | 231 | 0.710 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 5 | 0.700 |
Why?
|
| Bioprosthesis | 2 | 2020 | 40 | 0.700 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2020 | 40 | 0.690 |
Why?
|
| Polytetrafluoroethylene | 2 | 2018 | 24 | 0.690 |
Why?
|
| Heart Diseases | 4 | 2023 | 350 | 0.690 |
Why?
|
| Palliative Care | 6 | 2025 | 706 | 0.690 |
Why?
|
| Heart-Assist Devices | 2 | 2023 | 539 | 0.680 |
Why?
|
| Plasma Cells | 1 | 2020 | 66 | 0.680 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2022 | 385 | 0.680 |
Why?
|
| Abnormalities, Multiple | 2 | 2013 | 178 | 0.670 |
Why?
|
| Aortic Diseases | 3 | 2022 | 113 | 0.670 |
Why?
|
| Vascular Stiffness | 6 | 2021 | 467 | 0.660 |
Why?
|
| Thrombosis | 1 | 2023 | 343 | 0.660 |
Why?
|
| Multiple Myeloma | 5 | 2025 | 125 | 0.650 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2023 | 48 | 0.650 |
Why?
|
| Aorta | 9 | 2020 | 408 | 0.640 |
Why?
|
| Aortography | 3 | 2017 | 51 | 0.640 |
Why?
|
| Follow-Up Studies | 16 | 2023 | 4887 | 0.620 |
Why?
|
| Aneurysm, False | 1 | 2019 | 47 | 0.620 |
Why?
|
| Stenosis, Pulmonary Artery | 1 | 2018 | 4 | 0.620 |
Why?
|
| Mitral Valve | 2 | 2016 | 85 | 0.610 |
Why?
|
| Pediatrics | 4 | 2023 | 1049 | 0.610 |
Why?
|
| Time Factors | 22 | 2024 | 6543 | 0.600 |
Why?
|
| Emergencies | 1 | 2019 | 155 | 0.600 |
Why?
|
| Adult | 44 | 2025 | 35495 | 0.590 |
Why?
|
| Fontan Procedure | 5 | 2020 | 173 | 0.590 |
Why?
|
| Chromium Alloys | 1 | 2018 | 5 | 0.590 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 9 | 0.580 |
Why?
|
| Hypertension | 2 | 2020 | 1242 | 0.580 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 34 | 0.570 |
Why?
|
| Congresses as Topic | 1 | 2019 | 216 | 0.570 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 327 | 0.560 |
Why?
|
| Catheter Ablation | 2 | 2023 | 335 | 0.560 |
Why?
|
| Factor VIIa | 1 | 2017 | 39 | 0.560 |
Why?
|
| Coronary Artery Disease | 1 | 2024 | 679 | 0.560 |
Why?
|
| Foreign-Body Migration | 2 | 2017 | 34 | 0.560 |
Why?
|
| Hemoptysis | 1 | 2017 | 35 | 0.560 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2023 | 467 | 0.550 |
Why?
|
| Equipment Design | 9 | 2019 | 513 | 0.530 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 485 | 0.520 |
Why?
|
| Coronary Angiography | 4 | 2024 | 305 | 0.520 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2021 | 185 | 0.520 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2016 | 4 | 0.520 |
Why?
|
| Middle Aged | 35 | 2025 | 31090 | 0.500 |
Why?
|
| United Kingdom | 8 | 2018 | 257 | 0.490 |
Why?
|
| Videoconferencing | 4 | 2013 | 64 | 0.480 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 2515 | 0.480 |
Why?
|
| Pain | 1 | 2021 | 786 | 0.480 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2015 | 14 | 0.470 |
Why?
|
| Femoral Vein | 2 | 2011 | 32 | 0.460 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2024 | 529 | 0.460 |
Why?
|
| Hemostatic Techniques | 2 | 2011 | 45 | 0.450 |
Why?
|
| Probiotics | 1 | 2014 | 51 | 0.430 |
Why?
|
| Age Factors | 12 | 2024 | 3140 | 0.430 |
Why?
|
| Endocarditis | 1 | 2014 | 37 | 0.430 |
Why?
|
| Eczema | 1 | 2014 | 67 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1367 | 0.430 |
Why?
|
| Aortic Stenosis, Supravalvular | 1 | 2013 | 4 | 0.420 |
Why?
|
| Ventricular Function, Right | 5 | 2022 | 276 | 0.420 |
Why?
|
| Embolism, Air | 1 | 2013 | 13 | 0.420 |
Why?
|
| Williams Syndrome | 1 | 2013 | 13 | 0.420 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 101 | 0.420 |
Why?
|
| Loeys-Dietz Syndrome | 1 | 2013 | 6 | 0.410 |
Why?
|
| Coronary Stenosis | 1 | 2013 | 39 | 0.410 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 66 | 0.410 |
Why?
|
| Hemorrhage | 3 | 2011 | 678 | 0.410 |
Why?
|
| Infant, Low Birth Weight | 1 | 2013 | 135 | 0.400 |
Why?
|
| Aneurysm | 1 | 2013 | 30 | 0.400 |
Why?
|
| Pulmonary Circulation | 5 | 2019 | 430 | 0.400 |
Why?
|
| Stroke Volume | 6 | 2022 | 592 | 0.390 |
Why?
|
| Hypertension, Renovascular | 1 | 2011 | 15 | 0.380 |
Why?
|
| Absorbable Implants | 2 | 2020 | 35 | 0.380 |
Why?
|
| Kynurenine | 2 | 2024 | 114 | 0.380 |
Why?
|
| Renal Artery Obstruction | 1 | 2011 | 29 | 0.380 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 43 | 0.380 |
Why?
|
| Renal Artery | 1 | 2011 | 34 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2020 | 3386 | 0.370 |
Why?
|
| Tryptophan | 2 | 2024 | 178 | 0.360 |
Why?
|
| Suture Techniques | 1 | 2011 | 118 | 0.360 |
Why?
|
| Prospective Studies | 17 | 2024 | 7123 | 0.350 |
Why?
|
| Airway Obstruction | 2 | 2023 | 152 | 0.340 |
Why?
|
| Platinum | 2 | 2022 | 44 | 0.340 |
Why?
|
| Surgical Instruments | 1 | 2010 | 50 | 0.330 |
Why?
|
| Reproducibility of Results | 7 | 2024 | 3080 | 0.330 |
Why?
|
| Arterial Pressure | 3 | 2021 | 118 | 0.330 |
Why?
|
| Weight Gain | 1 | 2013 | 509 | 0.330 |
Why?
|
| Hand Deformities, Congenital | 1 | 2009 | 7 | 0.320 |
Why?
|
| Balloon Valvuloplasty | 3 | 2024 | 4 | 0.320 |
Why?
|
| Recovery of Function | 3 | 2024 | 641 | 0.320 |
Why?
|
| Coronary Circulation | 3 | 2022 | 138 | 0.320 |
Why?
|
| Postoperative Complications | 7 | 2020 | 2473 | 0.310 |
Why?
|
| Ontario | 4 | 2013 | 90 | 0.300 |
Why?
|
| Catheters | 2 | 2023 | 66 | 0.300 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2009 | 123 | 0.300 |
Why?
|
| Case-Control Studies | 9 | 2024 | 3377 | 0.290 |
Why?
|
| Ventricular Function, Left | 3 | 2020 | 527 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 1497 | 0.280 |
Why?
|
| Boronic Acids | 1 | 2007 | 37 | 0.280 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2019 | 37 | 0.280 |
Why?
|
| Nitric Oxide | 2 | 2024 | 901 | 0.280 |
Why?
|
| Off-Label Use | 2 | 2017 | 51 | 0.270 |
Why?
|
| Systole | 3 | 2022 | 191 | 0.270 |
Why?
|
| Cardiac Catheters | 2 | 2019 | 15 | 0.270 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 106 | 0.260 |
Why?
|
| Risk Factors | 16 | 2024 | 9745 | 0.260 |
Why?
|
| Pyrazines | 1 | 2007 | 86 | 0.260 |
Why?
|
| Aged | 24 | 2025 | 22032 | 0.260 |
Why?
|
| Heart Failure | 4 | 2021 | 2135 | 0.250 |
Why?
|
| Reference Values | 2 | 2024 | 793 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 2 | 2025 | 285 | 0.250 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 671 | 0.240 |
Why?
|
| Scimitar Syndrome | 1 | 2024 | 9 | 0.230 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 49 | 0.220 |
Why?
|
| North America | 3 | 2022 | 291 | 0.220 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2024 | 13 | 0.220 |
Why?
|
| Constriction, Pathologic | 2 | 2022 | 226 | 0.220 |
Why?
|
| United States | 8 | 2024 | 13826 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 1708 | 0.220 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.220 |
Why?
|
| Tomography, Optical Coherence | 2 | 2023 | 186 | 0.210 |
Why?
|
| Citrulline | 1 | 2024 | 44 | 0.210 |
Why?
|
| Tracheobronchomalacia | 1 | 2023 | 14 | 0.210 |
Why?
|
| Airway Extubation | 1 | 2024 | 54 | 0.210 |
Why?
|
| Vascular Closure Devices | 1 | 2023 | 6 | 0.210 |
Why?
|
| Electrocoagulation | 1 | 2023 | 37 | 0.210 |
Why?
|
| Societies, Medical | 2 | 2019 | 744 | 0.210 |
Why?
|
| Registries | 5 | 2024 | 1895 | 0.210 |
Why?
|
| Polymorphism, Genetic | 3 | 2004 | 639 | 0.200 |
Why?
|
| Pericardium | 1 | 2023 | 54 | 0.200 |
Why?
|
| Ventricular Remodeling | 2 | 2022 | 255 | 0.200 |
Why?
|
| Radiation Dosage | 1 | 2024 | 153 | 0.200 |
Why?
|
| Thrombectomy | 1 | 2023 | 58 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 181 | 0.200 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2002 | 16 | 0.200 |
Why?
|
| Thymidylate Synthase | 1 | 2002 | 12 | 0.200 |
Why?
|
| Arginine | 1 | 2024 | 265 | 0.200 |
Why?
|
| Ultrasonography, Interventional | 3 | 2018 | 128 | 0.200 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2022 | 8 | 0.190 |
Why?
|
| Drainage | 1 | 2023 | 164 | 0.190 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2020 | 202 | 0.190 |
Why?
|
| Patient Discharge | 1 | 2008 | 835 | 0.190 |
Why?
|
| Heart Bypass, Right | 1 | 2022 | 17 | 0.190 |
Why?
|
| Perfusion Imaging | 2 | 2019 | 56 | 0.190 |
Why?
|
| Amyloidogenic Proteins | 1 | 2021 | 16 | 0.190 |
Why?
|
| Regional Blood Flow | 2 | 2021 | 463 | 0.190 |
Why?
|
| Blood Volume | 2 | 2021 | 60 | 0.190 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 17 | 0.180 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 156 | 0.180 |
Why?
|
| Contrast Media | 1 | 2024 | 393 | 0.180 |
Why?
|
| Ventricular Function | 1 | 2021 | 61 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2022 | 329 | 0.180 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 90 | 0.170 |
Why?
|
| Pulse Wave Analysis | 2 | 2018 | 248 | 0.170 |
Why?
|
| Incidence | 4 | 2018 | 2636 | 0.170 |
Why?
|
| London | 2 | 2018 | 45 | 0.170 |
Why?
|
| Bronchial Diseases | 1 | 2020 | 37 | 0.170 |
Why?
|
| Endothelin-1 | 1 | 2022 | 179 | 0.170 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 7 | 0.170 |
Why?
|
| Protein Folding | 1 | 2021 | 264 | 0.170 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 203 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 756 | 0.170 |
Why?
|
| Device Removal | 3 | 2017 | 136 | 0.160 |
Why?
|
| Heart Function Tests | 1 | 2019 | 59 | 0.160 |
Why?
|
| Survival Rate | 4 | 2020 | 1869 | 0.160 |
Why?
|
| Stress, Mechanical | 5 | 2019 | 467 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2022 | 867 | 0.160 |
Why?
|
| Anxiety | 2 | 2021 | 962 | 0.160 |
Why?
|
| Thoracic Injuries | 1 | 2019 | 55 | 0.160 |
Why?
|
| Aortic Valve | 2 | 2019 | 347 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 742 | 0.160 |
Why?
|
| Cyanosis | 2 | 2016 | 16 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1267 | 0.160 |
Why?
|
| Vascular Access Devices | 1 | 2019 | 26 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 958 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 278 | 0.150 |
Why?
|
| Pain Measurement | 1 | 2021 | 506 | 0.150 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 191 | 0.150 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 73 | 0.150 |
Why?
|
| Length of Stay | 2 | 2024 | 1120 | 0.150 |
Why?
|
| Protein Conformation | 1 | 2021 | 861 | 0.150 |
Why?
|
| Marfan Syndrome | 1 | 2018 | 39 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2020 | 244 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1556 | 0.150 |
Why?
|
| Compressive Strength | 1 | 2018 | 69 | 0.150 |
Why?
|
| China | 1 | 2019 | 191 | 0.150 |
Why?
|
| Atrial Septum | 1 | 2018 | 3 | 0.150 |
Why?
|
| Pain Management | 1 | 2021 | 324 | 0.150 |
Why?
|
| Radiation Protection | 1 | 2018 | 36 | 0.150 |
Why?
|
| Turner Syndrome | 1 | 2018 | 51 | 0.150 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 378 | 0.140 |
Why?
|
| Thermodilution | 1 | 2017 | 13 | 0.140 |
Why?
|
| Noonan Syndrome | 1 | 2018 | 17 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 340 | 0.140 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 137 | 0.140 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 438 | 0.140 |
Why?
|
| Blood Flow Velocity | 4 | 2020 | 406 | 0.140 |
Why?
|
| Pressure | 3 | 2016 | 237 | 0.140 |
Why?
|
| Dilatation | 1 | 2017 | 59 | 0.140 |
Why?
|
| Ireland | 4 | 2019 | 27 | 0.140 |
Why?
|
| Cardiologists | 1 | 2017 | 45 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2740 | 0.130 |
Why?
|
| Swine | 1 | 2019 | 760 | 0.130 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 7055 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2002 | 2276 | 0.130 |
Why?
|
| Colorado | 2 | 2024 | 4406 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2012 | 572 | 0.130 |
Why?
|
| Vascular Remodeling | 1 | 2018 | 192 | 0.130 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 271 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 166 | 0.130 |
Why?
|
| Femoral Artery | 2 | 2023 | 173 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2016 | 67 | 0.130 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2016 | 12 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 57 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 2054 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 218 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 234 | 0.130 |
Why?
|
| Observer Variation | 1 | 2017 | 315 | 0.130 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2015 | 3 | 0.120 |
Why?
|
| Europe | 3 | 2024 | 363 | 0.120 |
Why?
|
| Body Weight | 2 | 2017 | 939 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2021 | 721 | 0.120 |
Why?
|
| Punctures | 2 | 2011 | 40 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 851 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2018 | 546 | 0.120 |
Why?
|
| Tricuspid Atresia | 1 | 2014 | 5 | 0.120 |
Why?
|
| Recurrence | 3 | 2013 | 1005 | 0.120 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2014 | 7 | 0.120 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2016 | 121 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 672 | 0.110 |
Why?
|
| Radiography | 3 | 2014 | 796 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 1304 | 0.110 |
Why?
|
| Skin Tests | 1 | 2014 | 100 | 0.110 |
Why?
|
| Transplantation, Autologous | 2 | 2011 | 211 | 0.110 |
Why?
|
| Computer Communication Networks | 1 | 2013 | 32 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2018 | 636 | 0.110 |
Why?
|
| Foramen Ovale, Patent | 1 | 2013 | 10 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2016 | 240 | 0.110 |
Why?
|
| Diseases in Twins | 1 | 2014 | 175 | 0.100 |
Why?
|
| Remote Consultation | 1 | 2013 | 46 | 0.100 |
Why?
|
| Home Care Services | 2 | 2013 | 225 | 0.100 |
Why?
|
| Canada | 1 | 2014 | 350 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 105 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1199 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2024 | 5409 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 299 | 0.100 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2023 | 26 | 0.100 |
Why?
|
| Ultrasonography | 3 | 2010 | 713 | 0.100 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2013 | 83 | 0.100 |
Why?
|
| Health Surveys | 1 | 2014 | 493 | 0.100 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2012 | 199 | 0.090 |
Why?
|
| Remission Induction | 2 | 2014 | 271 | 0.090 |
Why?
|
| Cystitis | 1 | 2011 | 22 | 0.090 |
Why?
|
| Starch | 1 | 2011 | 22 | 0.090 |
Why?
|
| Bandages | 1 | 2011 | 32 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 140 | 0.090 |
Why?
|
| Syndrome | 1 | 2011 | 339 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 2 | 2002 | 105 | 0.090 |
Why?
|
| Hypoxia | 3 | 2024 | 1084 | 0.090 |
Why?
|
| Vital Signs | 2 | 2021 | 41 | 0.090 |
Why?
|
| Hemostatics | 1 | 2011 | 49 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2002 | 112 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 240 | 0.090 |
Why?
|
| Serotonin | 2 | 2024 | 318 | 0.090 |
Why?
|
| Tertiary Care Centers | 3 | 2017 | 146 | 0.080 |
Why?
|
| Electrocardiography | 2 | 2013 | 608 | 0.080 |
Why?
|
| Teleradiology | 1 | 2009 | 5 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 164 | 0.080 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2020 | 36 | 0.080 |
Why?
|
| Exercise Test | 1 | 2013 | 612 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1875 | 0.080 |
Why?
|
| Patient-Specific Modeling | 2 | 2020 | 39 | 0.080 |
Why?
|
| Balloon Occlusion | 1 | 2009 | 34 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4057 | 0.080 |
Why?
|
| Telemedicine | 2 | 2008 | 788 | 0.080 |
Why?
|
| Electrodes, Implanted | 1 | 2009 | 106 | 0.080 |
Why?
|
| Health Care Costs | 2 | 2009 | 367 | 0.080 |
Why?
|
| Aortic Aneurysm | 1 | 2009 | 65 | 0.080 |
Why?
|
| Catheterization | 1 | 2009 | 174 | 0.080 |
Why?
|
| Pacemaker, Artificial | 1 | 2009 | 110 | 0.070 |
Why?
|
| Myocardial Contraction | 2 | 2020 | 335 | 0.070 |
Why?
|
| Critical Care | 1 | 2013 | 551 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2007 | 21 | 0.070 |
Why?
|
| Histocompatibility | 1 | 2007 | 26 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 82 | 0.070 |
Why?
|
| Bortezomib | 1 | 2007 | 45 | 0.070 |
Why?
|
| Telephone | 1 | 2008 | 167 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 1085 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2012 | 652 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2008 | 632 | 0.070 |
Why?
|
| Risk Assessment | 5 | 2023 | 3232 | 0.070 |
Why?
|
| Elastic Modulus | 2 | 2019 | 122 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 61 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 232 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2007 | 275 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 294 | 0.060 |
Why?
|
| Neonatal Screening | 1 | 2008 | 163 | 0.060 |
Why?
|
| Materials Testing | 2 | 2019 | 343 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5384 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 1446 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 253 | 0.060 |
Why?
|
| England | 3 | 2013 | 72 | 0.060 |
Why?
|
| Proteomics | 2 | 2023 | 1054 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 272 | 0.060 |
Why?
|
| Stroke | 1 | 2013 | 1070 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2004 | 1647 | 0.060 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 49 | 0.060 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2025 | 9 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2007 | 350 | 0.060 |
Why?
|
| Pregnancy | 2 | 2014 | 6390 | 0.060 |
Why?
|
| Kynurenic Acid | 1 | 2024 | 19 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2007 | 391 | 0.060 |
Why?
|
| Reoperation | 2 | 2018 | 541 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2005 | 1497 | 0.060 |
Why?
|
| Equipment Failure | 2 | 2019 | 105 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2007 | 252 | 0.060 |
Why?
|
| Prognosis | 5 | 2018 | 3773 | 0.060 |
Why?
|
| Social Support | 1 | 2008 | 582 | 0.060 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 422 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 77 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 25 | 0.050 |
Why?
|
| Biomarkers | 3 | 2023 | 3968 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 88 | 0.050 |
Why?
|
| Morbidity | 1 | 2024 | 300 | 0.050 |
Why?
|
| Cause of Death | 1 | 2005 | 392 | 0.050 |
Why?
|
| Equipment Failure Analysis | 2 | 2016 | 131 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2004 | 149 | 0.050 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2002 | 17 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2023 | 143 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2023 | 216 | 0.050 |
Why?
|
| Epoxide Hydrolases | 1 | 2002 | 13 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 45 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 317 | 0.050 |
Why?
|
| Germinal Center | 1 | 2002 | 57 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 148 | 0.050 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2021 | 16 | 0.050 |
Why?
|
| Replantation | 1 | 2021 | 31 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 1290 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2002 | 148 | 0.050 |
Why?
|
| Sirolimus | 1 | 2023 | 266 | 0.040 |
Why?
|
| Folic Acid | 1 | 2002 | 184 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 232 | 0.040 |
Why?
|
| Polydioxanone | 1 | 2020 | 3 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2002 | 263 | 0.040 |
Why?
|
| Photoplethysmography | 1 | 2020 | 18 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 114 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 69 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2016 | 1266 | 0.040 |
Why?
|
| Airway Management | 1 | 2020 | 44 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2020 | 121 | 0.040 |
Why?
|
| Smoking | 2 | 2004 | 1499 | 0.040 |
Why?
|
| Parents | 1 | 2008 | 1309 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 54 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 100 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 190 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 502 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 148 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2002 | 1019 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2004 | 938 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 666 | 0.040 |
Why?
|
| Collateral Circulation | 1 | 2019 | 18 | 0.040 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2020 | 145 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 400 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 83 | 0.040 |
Why?
|
| Autografts | 1 | 2019 | 42 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 28 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2023 | 541 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 247 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2018 | 60 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 635 | 0.040 |
Why?
|
| Altitude | 1 | 2023 | 462 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 424 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 99 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 149 | 0.040 |
Why?
|
| Poland | 1 | 2018 | 33 | 0.040 |
Why?
|
| Shear Strength | 1 | 2018 | 67 | 0.040 |
Why?
|
| Vascular Resistance | 2 | 2019 | 370 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 763 | 0.040 |
Why?
|
| Heart Rate | 2 | 2021 | 802 | 0.040 |
Why?
|
| Telemetry | 2 | 2008 | 39 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 592 | 0.040 |
Why?
|
| Cardiac Output | 2 | 2017 | 156 | 0.040 |
Why?
|
| Body Size | 1 | 2018 | 104 | 0.040 |
Why?
|
| Internet | 2 | 2013 | 615 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 35309 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2017 | 37 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 713 | 0.030 |
Why?
|
| Genotype | 1 | 2002 | 1835 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 1839 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 90 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2018 | 757 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 557 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 652 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 508 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 301 | 0.030 |
Why?
|
| Oxygen | 1 | 2018 | 915 | 0.030 |
Why?
|
| Ligation | 1 | 2013 | 87 | 0.030 |
Why?
|
| Acute Disease | 2 | 2009 | 978 | 0.030 |
Why?
|
| Alloys | 1 | 2013 | 33 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 526 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1613 | 0.020 |
Why?
|
| Software | 1 | 2017 | 606 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2017 | 601 | 0.020 |
Why?
|
| Hematoma | 1 | 2011 | 53 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2630 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2012 | 277 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2010 | 74 | 0.020 |
Why?
|
| Lung | 1 | 2023 | 3927 | 0.020 |
Why?
|
| Hospitals, District | 1 | 2009 | 6 | 0.020 |
Why?
|
| Northern Ireland | 1 | 2009 | 7 | 0.020 |
Why?
|
| Hospitals, General | 1 | 2009 | 21 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 514 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2017 | 1016 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2009 | 23 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 48 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 647 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 339 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2009 | 148 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 5050 | 0.020 |
Why?
|
| Siblings | 1 | 2007 | 215 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2010 | 846 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 662 | 0.020 |
Why?
|
| Asia | 1 | 2005 | 58 | 0.010 |
Why?
|
| Platelet Count | 1 | 2005 | 82 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2004 | 6 | 0.010 |
Why?
|
| International Cooperation | 1 | 2005 | 174 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 1584 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2005 | 148 | 0.010 |
Why?
|
| Codon | 1 | 2004 | 86 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2004 | 119 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 305 | 0.010 |
Why?
|
| Aging | 1 | 2014 | 1774 | 0.010 |
Why?
|
| Creatinine | 1 | 2005 | 491 | 0.010 |
Why?
|
| DNA Repair | 1 | 2004 | 206 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2002 | 8 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 28 | 0.010 |
Why?
|
| Karyotyping | 1 | 2002 | 107 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 1288 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 372 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 359 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 313 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 991 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 1965 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 1269 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 509 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2002 | 1173 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 3074 | 0.010 |
Why?
|
| Phenytoin | 1 | 1970 | 20 | 0.010 |
Why?
|
| Digoxin | 1 | 1970 | 27 | 0.010 |
Why?
|
| Mutation | 1 | 2002 | 3710 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 1970 | 57 | 0.000 |
Why?
|
| Dogs | 1 | 1970 | 382 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1970 | 320 | 0.000 |
Why?
|